GLP1R and chronic kidney disease: A high-quality meta-analysis involving 18 randomized controlled trials conducted by Zhang et al. demonstrated that among GLP-1 RAs, GLP-1 analogs significantly reduced MACE risk compared with Ex-4 analogs in patients with T2DM and chronic kidney disease (CKD) [64].